Founded by world-class researchers, clinicians, and drug developers from Massachusetts General Hospital and Harvard Medical School, Sensorium Therapeutics is biotechnology company leveraging cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. Beginning with evidence of efficacy and safety based on extensive long-term human use of plants and fungi, Sensorium's groundbreaking Biodynamic Discovery PlatformTM rapidly identifies, reproduces, adapts, and enhances targeted molecules and elevates their utility as modern medicines that can deliver transformational benefits to patients around the world.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/08/22 | $30,000,000 | Series A |
CU Healthcare Innovation Fund Iter Investments Ocama Partners Palo Santo Investors re.Mind Capital Route 66 Ventures Sante Ventures  WPSS.bio | undisclosed |
